Table 2

Consequences of psoriasis on outcomes in axSpA patients in univariable analysis at 6 years (N=589) and over 6 years of follow-up (N=708)

Psoriasis over 6 years of follow-up
(N=158)
No psoriasis over 6 years of follow-up
(N=431)
At 6 years: p value of univariable analysis
(N=589)
Over 6 years: linear mixed-effects model: univariable effect estimate (95% CI)
(N=708)
Key outcomes
 ASDAS-CRP, mean (SD)2.2 (0.9)2.1 (1.0)0.360.03 (−0.07 to 0.13)
 HAQ-AS, mean (SD) (0–3)0.60 (0.56)0.48 (0.49)0.070.01 (−0.04 to 0.05)
Other outcomes
 BASDAI, mean (SD) (0–100)36.3 (20.2)32.8 (21.7)0.090.55 (−1.61 to 2.71)
 BASFI, mean (SD) (0–100)25.9 (23.1)21.8 (20.6)0.13−0.52 (−2.61 to 1.56)
 ASQoL, mean (SD) (0–18)7.2 (5.4)6.4 (5.6)0.10−0.26 (−0.77 to 0.26)
 SF36
  Physical Component Summary, mean (SD) (0–100)42.7 (9.5)43.5 (9.7)0.370.03 (−0.91 to 0.97)
  Mental Component Summary, mean (SD) (0–100)43.3 (10.7)44.8 (11.4)0.07−0.13 (−1.29 to 1.04)
 Work loss (days per year), mean (SD)20.9 (32.8)21.2 (38.5)0.70
 Tender joint count, mean (SD) (0–53)3.4 (7.7)2.2 (4.6)0.110.20 (−0.66 to 1.07)
 Swollen joint count, mean (SD) (0–28)0.2 (1.3)0.1 (0.3)0.370.08 (0.02 to 0.15)
 MASES enthesitis index, mean (SD) (0–13)2.2 (3.1)2.0 (3.0)0.380.31 (0.004 to 0.62)
 CRP (mg/L), mean (SD)5.4 (8.5)4.8 (6.7)0.710.81 (−0.22 to 1.84)
 mSASSS*, mean (SD)(0–72)1.3 (4.7)1.0 (3.0)0.850.23 (0.01 to 0.59)
 Change in mSASSS between baseline and year 5, mean (SD)0.42 (2.0)0.42 (1.7)0.94
 Modified New York radiographic criteria during follow-up (local reading), n (%)48 (30.4)142 (32.9)0.62OR: 1.38 (0.57 to 3.35)
 NSAIDs intake since last visit, n (%)79 (63.7)196 (66.4)0.67OR: 0.92 (0.63 to 1.35)
 Current csDMARDs intake, n (%)35 (44.3)52 (34.9)0.21OR: 1.38 (0.70 to 2.74)
 Methotrexate intake at least once during follow-up, n (%)37 (25.5)42 (11.8)<0.001
OR: 2.57 (1.57; 4.21)
OR: 2.05 (0.84 to 5.00)
 bDMARDs intake at least once during follow-up, n (%)88 (55.7)164 (38.5)<0.001
OR: 2.01 (1.39; 2.91)
OR: 0.83 (0.38 to 1.81)
  • Effect estimates are beta unless otherwise indicated.

  • Values in bold are significant values at p-value <0.05 in univariable analyses at 6 years and over 6 years.

  • *Last assessment at year 5.

  • ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-C reactive protein; ASQoL, Ankylosing Spondylitis Quality of Life Scale; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARDs, biological DMARDs; csDMARDs, conventional synthetic disease modifying anti-rheumatic drugs ; HAQ-AS, Health Assessment Questionnaire for axSpA; MASES, Maastricht Ankylosing Spondylitis Enthesis score; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; SF-36, Short Form 36 Health Survey.